LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.12

Max

1.17

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+92.31% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-20M 155M
Eelmine avamishind	1.16
Eelmine sulgemishind	1.16

Uudiste sentiment

By Acuity

52%

48%

271 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15. märts 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15. märts 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15. märts 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15. märts 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 03:00 UTC

Uudisväärsed sündmused

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Iran War Delivers Windfall to America's Oil Country -- WSJ

14. märts 2026, 02:03 UTC

Tulu

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14. märts 2026, 01:32 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14. märts 2026, 00:29 UTC

Omandamised, ülevõtmised, äriostud

13D Filings -- Barrons.com

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

92.31% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 92.31%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

271 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.